Fotemustine plus dacarbazine for malignant melanoma.

Area of Science:

• Oncology
• Medical Oncology
• Clinical Pharmacology

Background:

• Metastatic melanoma remains a significant challenge in cancer treatment.
• Fotemustine and dacarbazine are chemotherapeutic agents with established roles in melanoma management.
• Optimizing combination regimens is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and toxicity of a combination regimen of fotemustine and dacarbazine in patients with metastatic melanoma.
• To assess the response rates in different metastatic sites, including central nervous system (CNS), visceral, and non-visceral sites.
• To compare the current findings with previously reported data and assess the safety profile.

Main Methods:

• A cohort of 119 patients with metastatic melanoma received a specific dosing schedule of fotemustine and dacarbazine.
• The treatment involved initial administration on days 1 and 8, followed by a rest period, and then a subsequent cycle every 3-4 weeks.
• Response rates and toxicity were assessed in evaluable patients.

Main Results:

• An overall response rate of 27.2% was observed, with 11.6% complete responses in 103 evaluable patients.
• The regimen showed activity against CNS metastases (26.3% response rate) and non-visceral sites (37.5% response rate).
• Main toxicities were hematological, including grade III-IV leukopenia (27.4%) and thrombocytopenia (23.4%), with overall toxicity being lower than fotemustine alone.

Conclusions:

• The combination of fotemustine and dacarbazine is an active outpatient regimen for metastatic melanoma.
• This regimen is particularly effective against CNS and non-visceral metastases.
• The observed hematological toxicity was significantly reduced compared to fotemustine monotherapy, suggesting a favorable safety profile for this combination.